ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,164.12
-0.19%
Dow Jones
39,118.86
-0.12%
Gold vs US Dollar
2,326.73
0.00%
Brent Oil
84.85
0.00%
Bitcoin
60,940.15
1.04%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. GRI Bio Inc (GRI)

  7. GRI Bio Inc (GRI) News

GRI Bio (GRI)

GRI Bio Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:GRI
DateTimeSourceHeadlineSymbolCompany
28/06/202421:05GlobeNewswire Inc.GRI Bio Announces Closing of $4.0 Million Public OfferingNASDAQ:GRIGRI Bio Inc
27/06/202414:00GlobeNewswire Inc.GRI Bio Announces Korea Patent Granted for Proprietary Natural Killer T (NKT) Cell ModulatorsNASDAQ:GRIGRI Bio Inc
27/06/202413:00GlobeNewswire Inc.GRI Bio Announces Pricing of $4 Million Public OfferingNASDAQ:GRIGRI Bio Inc
14/06/202413:05GlobeNewswire Inc.GRI Bio Announces Reverse Stock SplitNASDAQ:GRIGRI Bio Inc
11/06/202414:00GlobeNewswire Inc.GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor Pitch ConferenceNASDAQ:GRIGRI Bio Inc
22/05/202414:15GlobeNewswire Inc.GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) ProgramsNASDAQ:GRIGRI Bio Inc
21/05/202413:35GlobeNewswire Inc.GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)NASDAQ:GRIGRI Bio Inc
20/05/202413:45GlobeNewswire Inc.GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)NASDAQ:GRIGRI Bio Inc
14/05/202414:05GlobeNewswire Inc.GRI Bio to Present at Alliance Global Partner’s 2024 Healthcare Company ShowcaseNASDAQ:GRIGRI Bio Inc
13/05/202413:00GlobeNewswire Inc.GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:GRIGRI Bio Inc
29/04/202413:45GlobeNewswire Inc.GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on AutoimmunityNASDAQ:GRIGRI Bio Inc
25/04/202414:15GlobeNewswire Inc.GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment WebinarNASDAQ:GRIGRI Bio Inc
16/04/202413:35GlobeNewswire Inc.GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea PatentNASDAQ:GRIGRI Bio Inc
08/04/202413:35GlobeNewswire Inc.GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International ConferenceNASDAQ:GRIGRI Bio Inc
01/04/202412:35GlobeNewswire Inc.GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:GRIGRI Bio Inc
28/03/202413:00GlobeNewswire Inc.GRI Bio to Present at the MedInvest Biotech & Pharma Investor ConferenceNASDAQ:GRIGRI Bio Inc
14/03/202412:45GlobeNewswire Inc.GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell ModulatorsNASDAQ:GRIGRI Bio Inc
04/03/202413:30GlobeNewswire Inc.GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United KingdomNASDAQ:GRIGRI Bio Inc
02/02/202413:00GlobeNewswire Inc.GRI Bio Announces Pricing of $5.5 Million Public OfferingNASDAQ:GRIGRI Bio Inc
26/01/202413:05GlobeNewswire Inc.GRI Bio Announces Reverse Stock SplitNASDAQ:GRIGRI Bio Inc
05/12/202314:05GlobeNewswire Inc.GRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)NASDAQ:GRIGRI Bio Inc
27/11/202313:35GlobeNewswire Inc.GRI Bio (NASDAQ: GRI) Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT (“iNKT”) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)NASDAQ:GRIGRI Bio Inc
15/11/202313:05GlobeNewswire Inc.GRI Bio (NASDAQ: GRI) Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:GRIGRI Bio Inc
31/10/202312:45GlobeNewswire Inc.GRI Bio Presents Data Supporting Innovative Pipeline of NKT Cell Modulators for the Treatment of High-Value Inflammatory, Fibrotic and Autoimmune DiseasesNASDAQ:GRIGRI Bio Inc
19/10/202313:45GlobeNewswire Inc.GRI Bio Presents Translational Data Demonstrating Connection Between NKT Cells and the Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF) at the 2023 Pittsburgh-Ireland International Lung ConferenceNASDAQ:GRIGRI Bio Inc
17/10/202313:35GlobeNewswire Inc.GRI Bio Announces Partnership with the Respiratory Translational Research Collaboration to Advance Leading NKT Regulation Technology Targeting Earlier in the Inflammatory Cascade to Modulate Disease ProgressionNASDAQ:GRIGRI Bio Inc
11/10/202314:05GlobeNewswire Inc.GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Ask the CEO ConferenceNASDAQ:GRIGRI Bio Inc
05/10/202313:45GlobeNewswire Inc.GRI Bio Announces Publication of Comprehensive Invariant NKT (iNKT) Cell Review in Frontiers in Immunology Demonstrating a Key Role of Type 1 iNKT Cells in Modulating Various Fibrotic ConditionsNASDAQ:GRIGRI Bio Inc
06/09/202314:05GlobeNewswire Inc.GRI Bio to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:GRIGRI Bio Inc
23/08/202314:00GlobeNewswire Inc.GRI Bio Enters into Asset Purchase Agreement with Aardvark Therapeutics, Inc. for the Sale of Legacy Asset, ADAIRNASDAQ:GRIGRI Bio Inc
 Showing the most relevant articles for your search:NASDAQ:GRI

Your Recent History

BIT
UB78F9
Unicredit Bank
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved